삼출 나이관련황반변성에 의한 황반하출혈에서 유리체강내 애플리버셉트 단독요법의 임상적 효과

• 영문명: Intravitreal Aflibercept Monotherapy for Treating Submacular Hemorrhage Secondary to Neovascular Age-related Macular Degeneration
• 발행기관: 대한안과학회
• 저자명: 채수혜(Sue Hey Chae) 안소은(Soh Eun Ahn) 윤희성(Hee Seong Yoon)
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume59,number5, 1~7쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2018.04.30

영문 초록

Purpose: To evaluate the effects of intravitreal aflibercept injection in the treatment of submacular hemorrhage secondary to neovascular age-related macular degeneration (nAMD). Methods: This retrospective, observational study included patients diagnosed with nAMD with submacular hemorrhage treated with intravitreal aflibercept monotherapy. A total of 54 eyes of 54 patients were treated with an initial series of three monthly intravitreal aflibercept injections followed by as-needed injections. At the 6 month follow-up, changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and submacular hemorrhage area (SMH) were evaluated. Results: The mean preoperative BCVA was 0.79 ± 0.59 logMAR, which improved significantly to 0.53 ± 0.46 logMAR at 3 months and 0.48 ± 0.50 logMAR at 6 months (p < 0.001, in both). The CMT significantly decreased in all eyes: preoperative, 454.4 ± 131.5 μm, to 242.6 ± 39.7 μm at 6 months. The SMH was also reduced in all eyes: preoperative, 6.4 ± 4.8 disc areas (DAs) to 0.8 ± 1.4 DAs at 6 months. Ten eyes were diagnosed with typical nAMD (18.5%) and 44 eyes were diagnosed polypoidal choroidal vasculopathy (81.5%). There was no significant difference at 6 months in the visual outcomes of the subgroups. Conclusions: Intravitreal aflibercept monotherapy is well-tolerated as a treatment in maintaining or improving vision in patients with SMH secondary to nAMD. J Korean Ophthalmol Soc 2018;59(5):437-443

목차

대상과 방법

결 과

고 찰

키워드

Aflibercept Central macular thickness Neovascular age-related macular degeneration Submacular hemorrhag